Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et studie til at lære om undersøgelsesmedicinen PF-08634404 som enkeltbehandling og kombinationsbehandling hos voksne deltagere med en leverkræft kaldet hepatocellulært karcinom, der er for fremskreden til at blive fjernet ved kirurgi og kan have spredt sig til andre dele af kroppen.

6. oktober 2026 opdateret af: Pfizer

EN INTERVENTIONEL ÅBEN-LABEL FASE 1B/2-STUDIE TIL VURDERING AF SIKKERHED, FARMAKOKINETIK OG FORLØBIG EFFEKT AF PF-08634404 SOM MONOTERAPI OG KOMBINATIONSTERAPI HOS VOKSNE DELTAGERE MED UOPERABEL LOKALT FREMSKREDEN ELLER METASTATISK HEPATOCELLULÆRT KARCIOM

The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body.

To join the study, participants must meet the following conditions:

  • Be 18 years or older.
  • Have locally advanced or metastatic HCC.
  • Is not a candidate for complete surgical or loco-regional therapies.
  • Have not received any whole-body treatment for HCC.

Participants will receive PF-08634404 either alone or in combination with ipilimumab. The medicine will be given through intravenous (IV) infusions, which means it will be administered directly into a vein. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

138

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • California
      • Irvine, California, Forenede Stater, 92612
        • Rekruttering
        • Chao Family Comprehensive Cancer Center and Ambulatory Care
      • Irvine, California, Forenede Stater, 92612
        • Rekruttering
        • UCI Health - Irvine Infusion Pharmacy ACC
      • Irvine, California, Forenede Stater, 92612
        • Rekruttering
        • UCI Health - Irvine
      • Los Angeles, California, Forenede Stater, 90033
        • Rekruttering
        • USC/Norris Comprehensive Cancer Center
      • Los Angeles, California, Forenede Stater, 90033
        • Rekruttering
        • Keck Hospital of USC
      • Los Angeles, California, Forenede Stater, 90033
        • Rekruttering
        • USC/Norris Comprehensive Cancer Center / Investigational Drug Services
      • Los Angeles, California, Forenede Stater, 90033
        • Rekruttering
        • Los Angeles General Medical Center
      • Los Angeles, California, Forenede Stater, 90025
        • Rekruttering
        • START Los Angeles, LLC
      • Los Angeles, California, Forenede Stater, 90067
        • Rekruttering
        • LACN Century City
      • Orange, California, Forenede Stater, 92868
        • Rekruttering
        • UC Irvine Health - Chao Family Comprehensive Cancer Center
      • Pasadena, California, Forenede Stater, 91105
        • Rekruttering
        • Keck Medical Center of USC Pasadena
    • Florida
      • Land O' Lakes, Florida, Forenede Stater, 34638
        • Rekruttering
        • Moffitt Cancer Center at Speros
      • Ruskin, Florida, Forenede Stater, 33570
        • Rekruttering
        • Moffitt Cancer Center at SouthShore
      • Tampa, Florida, Forenede Stater, 33612
        • Rekruttering
        • Moffitt Cancer Center - McKinley Campus
      • Tampa, Florida, Forenede Stater, 33612
        • Rekruttering
        • Moffitt Cancer Center
      • Tampa, Florida, Forenede Stater, 33612
        • Rekruttering
        • Moffitt McKinley Hospital
      • Tampa, Florida, Forenede Stater, 33607
        • Rekruttering
        • Moffitt Cancer Center - International Plaza
      • Wesley Chapel, Florida, Forenede Stater, 33544
        • Rekruttering
        • Moffitt Cancer Center at Wesley Chapel
    • Illinois
      • Shiloh, Illinois, Forenede Stater, 62269
        • Rekruttering
        • Siteman Cancer Center - Shiloh
      • Shiloh, Illinois, Forenede Stater, 62269
        • Rekruttering
        • Memorial Hospital
    • Minnesota
      • Coon Rapids, Minnesota, Forenede Stater, 55433
        • Rekruttering
        • Allina Health Cancer Institute - Mercy Hospital
      • Minneapolis, Minnesota, Forenede Stater, 55407
        • Rekruttering
        • Allina Health Cancer Institute - Abbott Northwestern Hospital
      • Saint Paul, Minnesota, Forenede Stater, 55102
        • Rekruttering
        • Allina Health Cancer Institute - United Hospital
    • Missouri
      • City of Saint Peters, Missouri, Forenede Stater, 63376
        • Rekruttering
        • Siteman Cancer Center - St. Peters
      • Creve Coeur, Missouri, Forenede Stater, 63141
        • Rekruttering
        • Siteman Cancer Center - West County
      • Florissant, Missouri, Forenede Stater, 63031
        • Rekruttering
        • Siteman Cancer Center - North County
      • Kansas City, Missouri, Forenede Stater, 64111
        • Rekruttering
        • Saint Luke's Hospital of Kansas City
      • Kansas City, Missouri, Forenede Stater, 64111
        • Rekruttering
        • Saint Luke's Cancer Institute
      • St Louis, Missouri, Forenede Stater, 63108
        • Rekruttering
        • Siteman Cancer Center
      • St Louis, Missouri, Forenede Stater, 63110
        • Rekruttering
        • Washington University School of Medicine - Siteman Cancer Center
      • St Louis, Missouri, Forenede Stater, 63110
        • Rekruttering
        • Barnes-Jewish Hospital
      • St Louis, Missouri, Forenede Stater, 63129
        • Rekruttering
        • Siteman Cancer Center - South County
    • Nevada
      • Reno, Nevada, Forenede Stater, 89502
        • Rekruttering
        • Renown Regional Medical Center
      • Reno, Nevada, Forenede Stater, 89502
        • Rekruttering
        • Renown Health Medical Oncology
      • Reno, Nevada, Forenede Stater, 89502
        • Rekruttering
        • Renown Office of Clinical Research
    • North Carolina
      • Cary, North Carolina, Forenede Stater, 27518
        • Rekruttering
        • Duke Cancer Center Cary
      • Durham, North Carolina, Forenede Stater, 27710
        • Rekruttering
        • Duke Cancer Center
      • Durham, North Carolina, Forenede Stater, 27710
        • Rekruttering
        • Duke University - Main Hospital and Clinics
      • Durham, North Carolina, Forenede Stater, 27710
        • Rekruttering
        • Duke Cancer Center - Investigational Chemotherapy Service
      • Raleigh, North Carolina, Forenede Stater, 27609
        • Rekruttering
        • Duke Cancer Center Raleigh
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44106
        • Rekruttering
        • University Hospitals Cleveland Medical Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forenede Stater, 15212
        • Rekruttering
        • AHN Allegheny General Hospital
      • Pittsburgh, Pennsylvania, Forenede Stater, 15212
        • Rekruttering
        • AHN Cancer Institute at Allegheny General Hospital
    • Washington
      • Seattle, Washington, Forenede Stater, 98101
        • Rekruttering
        • Virginia Mason Medical Center
      • Seattle, Washington, Forenede Stater, 98109
        • Rekruttering
        • Fred Hutchinson Cancer Center
      • Seattle, Washington, Forenede Stater, 98195
        • Rekruttering
        • University of Washington Medical Center- Montlake
      • Fukuoka, Japan, 811-1395
        • Rekruttering
        • National Hospital Organization Kyushu Cancer Center
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 464-8681
        • Rekruttering
        • Aichi Cancer Center
    • Chiba
      • Kashiwa, Chiba, Japan, 277-8577
        • Rekruttering
        • National Cancer Center Hospital East
    • Osaka
      • Sakai, Osaka, Japan, 590-0197
        • Rekruttering
        • Kindai University Hospital- Osaka Medical Campus
    • Tokyo
      • Chuo-ku, Tokyo, Japan, 104-0045
        • Rekruttering
        • National Cancer Center Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200032
        • Rekruttering
        • Zhongshan Hospital,Fudan University
      • San Juan, Puerto Rico, 00909
        • Rekruttering
        • Pan American Center for Oncology Trials, LLC
    • United States of America
      • Dorado, United States of America, Puerto Rico, 00646
        • Rekruttering
        • Pan American Center for Oncology Trials, LLC - Dorado Office
      • Mayagüez, United States of America, Puerto Rico, 00680
        • Rekruttering
        • Pan American Center for Oncology Trials, LLC - Mayaguez Office
      • Ponce, United States of America, Puerto Rico, 00730
        • Rekruttering
        • Pan American Center for Oncology Trials, LLC - Ponce Office
      • Taichung, Taiwan, 407
        • Rekruttering
        • Taichung Veterans General Hospital
      • Tainan, Taiwan, 704
        • Rekruttering
        • National Cheng Kung University Hospital
      • Taipei, Taiwan, 10002
        • Rekruttering
        • National Taiwan University Hospital
      • Taipei, Taiwan, 112
        • Rekruttering
        • Taipei Veterans General Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • 18 years of age or older at screening.
  • Locally advanced or metastatic HCC with diagnosis confirmed by histology/cytology or clinically by AASLD criteria (for patients with cirrhosis). Participants without cirrhosis require histological confirmation of diagnosis.
  • Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies.
  • At least 1 measurable (as defined by RECIST 1.1 per investigator) and untreated lesion.
  • Adequate hepatic, liver, and renal function
  • No prior systemic therapy for HCC.
  • ECOG performance status 0 or 1
  • Child-Pugh Class A

Key Exclusion Criteria:

  • Moderate or severe ascites.
  • History of hepatic encephalopathy.
  • Participants with known active CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression.
  • Clinically significant risk of hemorrhage or fistula.
  • Participants with any history of another malignancy within 3 years.
  • History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
  • Participants with active autoimmune diseases requiring systemic treatment within the past 2 years.
  • Clinically significant cardiovascular disease within 6 months prior to the first dose.
  • Major surgery or severe trauma within 4 weeks prior to the first dose or planned major surgery during the study.
  • History of severe bleeding tendency or coagulation dysfunction.
  • History of severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding, including bleeding event due to esophageal and/or gastric varices, within 6 months prior to the first dose.
  • Participants with acute, chronic or symptomatic infections.
  • Participants with history of immunodeficiency.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Phase 1b

Participants will be allocated to sequential dose levels of PF-08634404 and ipilimumab.

Solution for infusion

Solution for infusion

Andre navne:
  • YERVOY
Eksperimentel: Phase 2

Participants will be randomized to receive either PF-08634404 monotherapy or PF-08634404 combined with ipilimumab.

Solution for infusion

Solution for infusion

Andre navne:
  • YERVOY

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Participants With Adverse Events
Tidsramme: Through end of study and up to approximately 24 months

Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.

Through end of study and up to approximately 24 months
Phase 1b: Number of participants with Dose limiting toxicities (DLT)
Tidsramme: Through 90 days after the last dose of study intervention; Approximately 24 months

DLTs are a predefined set of adverse events that are at least possibly related to any or all of the study interventions. The number of participants who experienced DLTs during the DLT observation period.

Through 90 days after the last dose of study intervention; Approximately 24 months
Phase 2: Confirmed Overall Response Rate (ORR) using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 24 months

ORR is the proportion of participants with a best overall response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 by investigator.

Approximately 24 months
Phase 2: Recommended dose of PF-08634404 in combination with ipilimumab
Tidsramme: Approximately 24 months

The doses of PF-08634404 and ipilimumab selected to be used in combination based on safety, tolerability, pharmacokinetics, and initial anti-tumor efficacy from Phase 2.

Approximately 24 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Phase 1b: Confirmed Objective Response Rate (ORR) using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 24 months

ORR is the proportion of participants with a best overall response of confirmed Complete Response (CR) or confirmed Partial Response (PR) per RECIST 1.1 by investigator.

Approximately 24 months
Duration of Response (DOR) per RECIST 1.1 by investigator
Tidsramme: Approximately 24 months

DOR is the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first.

Approximately 24 months
Progression Free Survival (PFS) per RECIST 1.1 by investigator
Tidsramme: Approximately 24 months

PFS is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first.

Approximately 24 months
Overall Survival (OS)
Tidsramme: Approximately 24 months

OS is defined as the time from the date of first dose to the date of death due to any cause.

Approximately 24 months
Number of Participants With Clinical Laboratory Abnormalities
Tidsramme: Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (assessed up to approximately 24 months)

Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing

Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (assessed up to approximately 24 months)
Pharmacokinetics (PK): Serum concentrations of PF-08634404
Tidsramme: Up to 24 months

Predose and/or postdose concentrations of PF-08634404 in combination with ipilimumab.

Up to 24 months
Incidence of antidrug antibody against PF-08634404
Tidsramme: Up to 24 months

To evaluate immunogenicity of PF-08634404 in combination with ipilimumab.

Up to 24 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Pfizer CT.gov Call Center, Pfizer

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. december 2025

Primær færdiggørelse (Anslået)

18. oktober 2027

Studieafslutning (Anslået)

17. oktober 2028

Datoer for studieregistrering

Først indsendt

7. november 2025

Først indsendt, der opfyldte QC-kriterier

7. november 2025

Først opslået (Faktiske)

12. november 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

8. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner